Short Script: Why MOTS-C Works for Some People and Not Others

Your cells are not broken. They just might not be ready.

MOTS-c is a peptide that comes from your mitochondria, specifically from a small stretch of mitochondrial DNA that encodes it, and it travels from muscle tissue into the bloodstream where it acts as a signaling molecule. It was only identified in 2015, and the mechanism behind it is more conditional than most people realize.

Here is the full chain before anything else. MOTS-c activates something called AMPK, which stands for AMP-activated protein kinase, and AMPK is essentially your cell's low-energy sensor. When energy drops, AMPK flips on and tells the cell to burn more fat, build more mitochondria, and pull glucose out of the blood more efficiently. MOTS-c is not doing any of those things directly. It is activating the switch that tells your cell to do them. The switch then depends on the cell having enough functional machinery to actually carry out those instructions. That is the whole chain, and that is where the whole conversation about why MOTS-c fails lives.

Now zoom into the first place it can break down.

Mitochondria are both the source of MOTS-c and the thing MOTS-c is trying to improve, and that creates a dependency that most people overlook. If your mitochondria are damaged, they produce less MOTS-c naturally. Fine, so you inject exogenous MOTS-c to compensate. But the signal MOTS-c sends still has to be received and executed by mitochondria, and if they are damaged beyond a functional threshold, the signal goes nowhere.

A 2020 study tested this directly by adding MOTS-c to cells carrying a severe mitochondrial DNA mutation called the 3243 A to G mutation. Neither exogenous MOTS-c nor any attempt to boost endogenous production improved mitochondrial function in those cells. The machinery was too compromised to respond. The signal arrived, and nothing happened.

Now, most people do not have a rare genetic mitochondrial mutation. But accumulated mitochondrial damage from years of oxidative stress, poor sleep, sedentary behavior, and metabolic dysfunction produces a functionally similar situation, not as extreme, but enough to blunt response significantly. This is why the sequencing matters. If the mitochondria are not functional enough to execute the AMPK signal, injecting more MOTS-c is like giving more instructions to a factory where the machines are broken. You can send all the orders you want.

The repair step, something like SS-31 which works by reducing oxidative stress on the inner mitochondrial membrane, comes before MOTS-c for this reason. You are not optimizing the signal. You are first restoring the machinery that reads it.

The second place the system can fail is AMPK suppression, and this one is subtle.

AMPK does not exist in a vacuum. It is constantly being held in check by upstream signals, and insulin is one of the primary ones. When insulin is chronically elevated, as it tends to be with excess body fat and low physical activity, AMPK activity gets suppressed as a downstream consequence. A 2013 review found that AMPK inhibition is actually an early event in the development of insulin resistance, not just a side effect of it. So by the time someone is significantly overweight and sedentary, their AMPK pathway may already be running at a fraction of its normal sensitivity.

MOTS-c tries to activate AMPK from one direction, through the folate cycle inside the cell. But if insulin signaling is simultaneously pushing AMPK down with significant force, the net effect is weak. The 2015 Cell Metabolism study showed clear results in obese mice treated with MOTS-c, including prevention of diet-induced obesity and improved insulin sensitivity, but those were mice without the decades of mitochondrial and metabolic wear that a sedentary person in their forties or fifties carries. The animal results are real. They just do not map cleanly onto a population with deeper systemic dysfunction.

Exercise changes the equation in a specific and measurable way. A 2021 Nature Communications study measured MOTS-c levels in skeletal muscle during exercise and found an 11.9-fold increase over baseline. That is not a modest bump. That is the system working exactly as it was designed to work, with the body generating a massive MOTS-c pulse to drive mitochondrial adaptation in response to energy demand. The same study found that this increase in circulating MOTS-c returned to baseline within four hours of exercise ending.

That four-hour window matters for how you think about dosing. If natural MOTS-c is gone from circulation within hours, then exogenous MOTS-c is likely operating on a similar timeline. Injecting once per week means the signal is active for a small fraction of the total time, roughly a few hours out of 168. Three times per week, timed close to periods of high energy demand like before training, keeps the AMPK signal more consistently elevated and more closely mimics the rhythm the body uses naturally.

The exercise point is not just about amplifying the peptide's effect. Exercise itself is one of the most potent activators of AMPK that exists, and it does so through multiple pathways simultaneously. When someone who is already training injects MOTS-c, they are adding a signal to a system that is already primed and responsive. When someone who is not exercising injects MOTS-c, they are sending a signal to a system that has been conditioned to resist it.

The practical sequence, then, is not complicated but it is ordered. Address mitochondrial health first. Establish consistent physical activity so AMPK is not chronically suppressed. Then use MOTS-c at a frequency that keeps the signal present across the week, timed around demand.

Genetics will always introduce individual variation, and that is true for every signaling compound. But the gap between someone who responds well to MOTS-c and someone who does not is far more often explained by the state of their metabolic foundation than by anything unusual about the peptide itself.

MOTS-c does not create metabolic health. It amplifies a system that is already capable of generating it.

---

References

1. Ahn CH, Choi EH, Kong BS, Cho YM. "Effects of MOTS-c on the mitochondrial function of cells harboring 3243 A to G mutant mitochondrial DNA." Molecular Biology Reports. 2020;475:4093-4098. Finding: Neither exogenous nor endogenous MOTS-C improved mitochondrial function in cells with severe genetic mitochondrial DNA damage 3243 A>G mutation. Source
2. Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications. 2021;121:470. Finding: Skeletal muscle MOTS-C increased 11.9-fold after exercise; circulating levels returned to baseline within 4 hours. Late-life treatment 3x/week improved grip strength, stride length, and walking capacity. Source
3. Lee C, Zeng J, Drew BG, et al. "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." Cell Metabolism. 2015;213:443-454. Finding: MOTS-C prevented diet-induced obesity and improved insulin sensitivity in mice via AMPK activation through folate cycle inhibition. 00061-3/fulltext Source
4. Ruderman NB, Carling D, Cline GW, et al. "AMPK, insulin resistance, and the metabolic syndrome." Journal of Clinical Investigation. 2013;1237:2764-2772. Finding: AMPK inhibition is an early event in insulin resistance development; exercise-induced AMPK activation is attenuated in patients with obesity. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness